Walvax Biotechnology Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Walvax Biotechnology Co., Ltd.
Some of China's makers of COVID-19 antivirals are fast-tracking neutralizing antibodies and peptide fusion inhibitors in clinical trials, while vaccine developers are embroiled in a tougher situation against the mutating coronavirus.
Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
As citizens in China grapple with the virtual end of pandemic restrictions and rush for medicines from cold remedies to traditional options, even some prescription antivirals such as Paxlovid are appearing online, while cheaper but unauthorized Indian generic versions have quickly sold out. Meanwhile, a renewed vaccination effort is targeting high-risk individuals and second booster shots as the country faces a huge surge in cases.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.